BioNTech SE (BNTX) vs Incyte Corporation (INCY)
A side-by-side comparison of BioNTech SE and Incyte Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 5, 2026. Differences are shown without an overall score or investment verdict.
BNTX
BioNTech SE
$92.18HealthcareDelayed quote: Aug 5, 2026, 4:00 PM EDT
INCY
Incyte Corporation
$119.80HealthcareAt close: Aug 5, 2026, 4:00 PM ET
Total return — BNTX vs INCY
growth of $100 · dividends reinvested · last 7yBNTX +556.0%INCY +60.2%BNTX compounded faster
BNTX INCY
BNTX vs INCY: by the numbers
- •INCY is the larger company ($24.28B vs $23.16B market cap).
- •INCY is profitable (27.71% net margin) while BNTX runs a net loss (-44.73%).
- •INCY grew revenue faster over the past five years (16.43% vs 2.16% CAGR).
Metrics side by side
Valuation
| Metric | BNTX | INCY |
|---|---|---|
| P/E ratio | N/A | 15.26 |
| Forward P/E | N/A | 24.93 |
| P/S ratio | 7.10 | 4.29 |
| P/B ratio | 1.08 | 3.93 |
| PEG ratio | N/A | 0.72 |
| EV / EBITDA | N/A | 10.85 |
| FCF yield | 6.41% | 7.70% |
Profitability
| Metric | BNTX | INCY |
|---|---|---|
| Gross margin | 73.26% | 92.62% |
| Operating margin | -22.63% | 31.57% |
| Net margin | -44.73% | 27.71% |
| ROE | -6.79% | 25.41% |
| ROIC | -3.14% | 20.58% |
Growth (annualized)
| Metric | BNTX | INCY |
|---|---|---|
| Revenue CAGR (5Y) | 2.16% | 16.43% |
| EPS CAGR (5Y) | N/A | 21.19% |
| FCF CAGR (5Y) | N/A | 33.69% |
| Total return CAGR (5Y) | -25.43% | 9.27% |
Frequently asked
- Which has grown faster, BNTX or INCY?
- Over the past five years, INCY grew revenue faster — BNTX at a 2.16% CAGR versus INCY at 16.43%.
- Is BNTX or INCY more profitable?
- INCY runs the higher net margin — BNTX at -44.73% versus INCY at 27.71%.
- How have BNTX and INCY total returns compared?
- Over the past 5 years, BNTX delivered -25.43% and INCY delivered 2.81% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
BioNTech SE P/E ratioIncyte P/E ratioBioNTech SE dividend yieldIncyte dividend yieldBioNTech SE ROEIncyte ROEBioNTech SE operating marginIncyte operating marginBioNTech SE revenue growthIncyte revenue growthBioNTech SE free cash flowIncyte free cash flow
BioNTech SE & Incyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 5, 2026.